CNBC
Novo Nordisk's raised forecast fails to change the debate over its obesity business
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Related stories
Bloomberg
BusinessAug 5, 2026 · 1 min
Schaeffler Targets 1,300 Job Cuts With Early Pension Push
Bloomberg
Bloomberg
BusinessAug 5, 2026 · 1 min
Moove Hits $2.1 Billion Valuation in Mubadala-Led Fundraising
Bloomberg
The Guardian
BusinessAug 5, 2026 · 1 min
Asian shares jump on AI trade revival despite SpaceX, AMD setbacks, as oil prices dip – business live
The Guardian
Bloomberg
BusinessAug 5, 2026 · 1 min
Glencore Has Taken a Provision on Radiant World Exposure
Bloomberg